dc.contributor.author | Bermingham, SL | en_US |
dc.contributor.author | Hughes, R | en_US |
dc.contributor.author | Fenu, E | en_US |
dc.contributor.author | Sawyer, LM | en_US |
dc.contributor.author | Boxall, E | en_US |
dc.contributor.author | Kennedy, PT | en_US |
dc.contributor.author | Dusheiko, G | en_US |
dc.contributor.author | Hill-Cawthorne, G | en_US |
dc.contributor.author | Thomas, H | en_US |
dc.date.accessioned | 2019-03-04T15:20:43Z | |
dc.date.available | 2015-05-28 | en_US |
dc.date.issued | 2015-09 | en_US |
dc.identifier.issn | 1098-3015 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/55748 | |
dc.format.extent | 800 - 809 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | VALUE IN HEALTH | en_US |
dc.subject | antiviral treatment | en_US |
dc.subject | chronic hepatitis B | en_US |
dc.subject | cost-effectiveness analysis | en_US |
dc.subject | interferon-alpha | en_US |
dc.subject | nucleosides | en_US |
dc.subject | nucleotides | en_US |
dc.title | Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom | en_US |
dc.type | Article | |
dc.rights.holder | © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). | |
dc.identifier.doi | 10.1016/j.jval.2015.05.007 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363479800009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 6 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 18 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |